The open letter from Eli Lilly is a proactive measure to ensure regulatory compliance and maintain trust with patients, healthcare providers, and investors. While it does not introduce new information about the company's financials or market performance, it reinforces the company's ethical stance, which can have a positive impact on its reputation. However, since the letter is focused on compliance rather than financial or market developments, the short-term impact on the stock price is likely to be neutral.